ReviewAnnals of surgical oncology2017
Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment.
Review in Annals of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- Surgical Management of Patients with Parotid Involvement from Non-Melanoma Skin Cancer of the Head and Neck.Journal of personalized medicine · 2024Article
- Cutaneous Metastase of Rectal Neuroendocrine Carcinoma Revealed onMolecular imaging and radionuclide therapy · 2023Article
- Article
- Photoplethysmography for demarcation of cutaneous squamous cell carcinoma.Scientific reports · 2021Article
- Evidence and Considerations on Treatment of Small Size Merkel Cell Head and Neck Carcinoma.International archives of otorhinolaryngology · 2020Article
- Nodal Merkel Cell Carcinoma in Head and Neck Lesions with an Unknown Primary: A Case Report in Light of the Literature.Yonago acta medica · 2019Article
- Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients.Cancers · 2018Article
- Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America.Journal of global oncology · 2018Review
- Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.In vivo (Athens, Greece)Article
- Concurrent Merkel Cell Carcinoma and Bowen's Disease in a Young Lady.Indian journal of dermatologyArticle
- Merkel Cells: A Collective Review of Current Concepts.International journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMerkel cell carcinoma (MCC) is a rare, aggressive tumor that often occurs in the head and neck region. Because of these features, the classifications and diagnostic and treatment regimens are frequently modified. Especially in the anatomically complex head and neck region, it is crucial to be aware of the current recommendations for diagnostics and treatment of MCC to ensure appropriate treatment. This overview aims to summarize the currently available literature.
methodsThe authors reviewed the relevant literature and international guidelines for MCC from 2012 to 2017 with respect to epidemiology and prognosis, diagnostic procedures and imaging, surgery, radiation, systemic treatment, and aftercare. These results were compared with existing guidelines, some of them current, and recommendations were derived.
resultsMarked developments in imaging have resulted in an increased use of functional imaging. The surgical concepts have changed regarding safety margins and the use of sentinel node biopsies. In systemic treatment, a move from conventional agents toward immuno-oncology can be observed.
conclusionsFor staging, it is important to be as exact as possible using functional imaging (e.g., positron emission tomography/computed tomography scan), especially in the head and neck area with its complex lymph drainage. This often plays an especially important role in early stages of the tumor, when the resection margin can be reduced to preserve the organ. Aftercare also should include functional imaging. In an advanced, metastatic stage, immuno-oncology (PD-1, PD-L1, CTLA-4) is superior to the previous methods of systemic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.